PurIST^® test, now commercially available through Tempus for clinical use, identifies the molecular subtype of patients with unresectable stage III or stage IV pancreatic ductal adenocarcinoma (PDAC).

PurIST^® utilizes RNA sequencing information to classify patients with PDAC into either a basal or classical subtype, and may help guide clinical management. Patients with a classical subtype were found to have an overall better prognosis and superior median overall survival when treated with first-line FOLFIRINOX, compared to patients with a basal subtype. (Rashid NU et al.,2020; Wenric S, et al.,2023)

 

1. Rashid NU et al. Purity independent subtyping of tumors (PurIST), a clinically robust, single-sample classifier for tumor subtyping in pancreatic cancer. Clinical Cancer Research. 2020;26(1):82-92. doi: 10.1158/1078-0432.CCR-19-1467
2. Wenric S, Davison JM, Guittar J, et al. Real-world data validation of the purist pancreatic ductal adenocarcinoma gene expression classifier and its prognostic implications. medRxiv. Preprint posted online February 24, 2023. doi:10.1101/2023.02.23.23286356